Eli Lilly Eyes Label Expansion For Leukemia Drug

Eli Lilly and Co. (NYSE: LLY ) said Sunday that its Phase 3 BRUIN CLL-322 trial met its primary endpoint , with the addition of Jaypirca (pirtobrutinib) to venetoclax and rituximab significantly improving progression-free survival in patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL). The study found that adding Jaypirca to a time-limited two-year regimen of venetoclax and rituximab reduced the risk of disease progression or death by 45% compared with venetoclax and rituximab alone. data-variant="card" data-news-mode="manual" > Read Also: Eli Lilly Highlights Weight Loss Benefits For Women Across Menopausal Stages Phase 3 Trial Delivers Strong Progression-Free Survival Benefit The BRUIN CLL-322 study enrolled 639 patients with relapsed or refractory CLL/SLL, nearly 80% of whom had previously received a covalent BTK inhibitor. Participants ... Full story available on Benzinga.com